Primary Hyperaldosteronism in the Hypertensive Disease

Fardella, Carlos E.; Carvajal, Cristian A.; Mosso, Lorena M.
March 2006
Current Hypertension Reviews;2006, Vol. 2 Issue 1, p33
Academic Journal
Primary aldosteronism (PA) is one of the potentially curable forms of hypertension. The hypertension is secondary to aldosterone action in the kidney, reabsorbing sodium and water that increases the intravascular volume and blood pressure. PA was previously believed to account for less than 1% of hypertensive patients when hypokalemia is used as screening method. However, recent studies using the plasma aldosterone to renin activity ratio (ARR) as screening test have demonstrated a high prevalence of PA in hypertensive populations. This prevalence vary depending on the severity of hypertensive disease being higher in stages 2 (8.55%) and 3 (13.5%) of the disease. Only a small proportion of PA patients (between 9 and 37%) are hypokalemic. The diagnosis of PA is advocated to confirm the autonomy of aldosterone secretion from the renin-angiotensin system and to differentiate the clinical subtypes of the disease. The most common subtypes of PA are idiopathic aldosteronism and aldosterone-producing adenoma. Other causes are glucocorticoid-remediable aldosteronism, unilateral or primary adrenal hyperplasia and adrenal carcinoma. This article reviews the new data about prevalence, diagnosis criteria and describes the clinical, biochemical and genetic characteristics of the different subtypes of the disease.


Related Articles

  • The Resurgence of Aldosterone in Hypertension and Cardiovascular Disease. Freel, E. Marie; Connell, John M. C. // Current Hypertension Reviews;2006, Vol. 2 Issue 1, p21 

    Aldosterone is a key cardiovascular hormone. Recent studies have illustrated its role in cardiac fibrosis and left ventricular hypertrophy as well as in impaired vascular reactivity. Moreover, many of these actions have been shown to be independent of its known effects on blood pressure. In a...

  • Aldosterone synthase inhibitors in hypertension: current status and future possibilities. Hargovan, Milan; Ferro, Albert // JRSM Cardiovascular Disease;Jan-Dec2014, Vol. 3, p1 

    The renin-angiotensin aldosterone system is a critical mechanism for controlling blood pressure, and exerts most of its physiological effects through the action of angiotensin II. In addition to increasing blood pressure by increasing vascular resistance, angiotensin II also stimulates...

  • Using Plasma Renin (PRA) Testing to Design Follow-Up Drug Treatment Strategies in Hypertensive Patients Already Taking Antirenin System Drugs. Sealey, Jean E.; Laragh, John H. // American Journal of Hypertension;Sep2009, Vol. 22 Issue 9, p950 

    The article presents a commentary on the study about using plasma renin (PRA) testing to design drug treatment strategies in hypertensive patients. According to the authors, the information provided by the test can be used to determine whether the patient is more likely to respond to a...

  • Clinical Relevance of Plasma Renin Activity in Hypertensive Patients. Mroczek, William J. // Angiology;Apr1978, Vol. 29 Issue 4, p296 

    Focuses on the clinical relevance of plasma renin activity in hypertensive patients. History of the identification of plasma renin; Advances in the development of inhibitors of the renin angiotensin system; New treatment approaches.

  • Conn's Syndrome: A Diagnostic Dilemma. Case Report. Butt, Waqas Tariq; Butt, Muhammad Umer; Gauhar, Tooba Mahmud; Khawaja, Ali Azim; Afzal, Ameer; Ahmed, Ashfaq; Azim, Khawaja Muhammad // Internet Journal of Surgery;2010, Vol. 24 Issue 1, p1 

    Conn's syndrome or primary hyperaldosteronism is characterized by hypertension, hypokalemia and increased ratio of plasma aldosterone concentration (ng/dl) to plasma renin activity (ng/ml per hour). Primary aldosteronism occurs most commonly due to aldosterone producing adenoma (Conn's syndrome)...

  • Essential Hypertension: A Metabolic Cause? A Hypothesis. Macieira-Coelho, Eduardo; Garcia-Alves, Mário; Reis-Valle, António // Angiology;May1985, Vol. 36 Issue 5, p305 

    Forty-five hypertensive patients, 28 women and 17 men, age range between 35 and 65 years (mean 50 years), with blood pressures which current therapy did not succeed to control, were submitted to several examinations in order to identify the cause of their hypertension. We found isolated or...

  • Comparative Effects of Pindolol and Hydrochlorothiazide in Black Hypertensive Patients. Moser, Marvin; Lunn, John // Angiology;Aug1981, Vol. 32 Issue 8, p561 

    This article focuses on the comparative effects of pindolol and hydrochlorothiazide in black hypertensive patients. Most American investigators agree and the Second Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure has again recommended that thiazide...

  • Aliskiren. Siragy, Helmy M.; Kar, Santwana; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Oct2007, Vol. 6 Issue 10, p779 

    Aliskiren (Tekturna; Speedel/Novartis) is the first in a new class of drugs that inhibit the protease renin, which has a key role in the regulation of blood pressure. It was approved by the US FDA for the treatment of hypertension in March 2007, and approved in Europe in August 2007 (where it...

  • Potassium and norepinephrine- or angiotensin-mediated pressor control in pre-hypertension. Bianchetti, Mario G.; Weidmann, Peter; Beretta-Piccoli, Carlo; Ferrier, Claudia // Kidney International;Apr1987, Vol. 31 Issue 4, p956 

    Blood pressure (BP), plasma electrolytes, renin, aldosterone, angiotensin 11 (AII) or catecholamines, the chronotropic effects of intravenous isoproterenol. norepinephrine (NE)or AII, the pressor responses to NE or AII, and the relationship between plasma AII and aldosterone concentrations were...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics